- cafead Feb 11, 2021 at 10:42: PM
via Novartis’ Sandoz is doubling down on antibiotics with a hefty deal for GlaxoSmithKline’s cephalosporin business.
Generics-focused Sandoz will pay $350 million up front and up to $150 million in milestone payments for Zinnat, Zinacef and Fortum, established antibiotic brands sold in more than 100 countries.
article source
Generics-focused Sandoz will pay $350 million up front and up to $150 million in milestone payments for Zinnat, Zinacef and Fortum, established antibiotic brands sold in more than 100 countries.
article source